Georgia CTSA Investigator Dr. Suresh Ramalingam in the News as PI on Study Led by Winship
A study led by Winship Cancer Institute of Emory University offers new insight into what causes resistance to the non-small cell lung cancer (NSCLC) medication osimertinib that may prove valuable in developing more effective NSCLC therapies. Suresh S. Ramalingam, MD, is the Executive Director at Winship and leads the growth and development of cancer research, clinical care, and education.